Oct 26, 2026
Host Dr. Jake New interviews Dr. Alexander Sherry and Dr. Chad Tang about their JCO article, "Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets From the Phase II Randomized EXTEND Trial." They discuss the significance of...
Oct 24, 2026
What long-term outcomes can be achieved with neoadjuvant cemiplimab, and how does immunotherapy reshape the treatment landscape for advanced cutaneous squamous cell carcinoma? Host Dr. Davide Soldato interviews Dr. Neil Gross on his simultaneous publication presented at ESMO 2026 "A Phase 2 Study of Neoadjuvant...
Oct 8, 2026
What pCR rates can be achieved with neoadjuvant THP, and which patients are most likely to respond? Host Dr. Davide Soldato interviews Dr. Nadine Tung on her article, “Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary...